Annual FCF
-$20.74 M
+$53.47 M+72.05%
31 December 2023
Summary:
Rigel Pharmaceuticals annual free cash flow is currently -$20.74 million, with the most recent change of +$53.47 million (+72.05%) on 31 December 2023. During the last 3 years, it has risen by +$32.70 million (+61.19%). RIGL annual FCF is now -148.04% below its all-time high of $43.18 million, reached on 31 December 2010.RIGL Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$21.67 M
+$21.59 M+26986.25%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly free cash flow is currently $21.67 million, with the most recent change of +$21.59 million (+26986.25%) on 30 September 2024. Over the past year, it has increased by +$23.03 million (+1694.48%). RIGL quarterly FCF is now -71.96% below its all-time high of $77.28 million, reached on 30 June 2010.RIGL Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$10.36 M
+$23.03 M+181.75%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM free cash flow is currently $10.36 million, with the most recent change of +$23.03 million (+181.75%) on 30 September 2024. Over the past year, it has increased by +$46.84 million (+128.39%). RIGL TTM FCF is now -77.03% below its all-time high of $45.09 million, reached on 31 March 2011.RIGL TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +72.0% | +1694.5% | +128.4% |
| 3 y3 years | +61.2% | +307.0% | +25.7% |
| 5 y5 years | +65.4% | +244.5% | +149.0% |
RIGL Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -495.0% | +72.0% | at high | +183.8% | at high | +114.0% |
| 5 y | 5 years | -495.0% | +72.0% | -60.5% | +183.8% | at high | +114.0% |
| alltime | all time | -148.0% | +80.4% | -72.0% | +174.5% | -77.0% | +109.6% |
Rigel Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $21.67 M(>+9900.0%) | $10.36 M(-181.8%) |
| June 2024 | - | $80.00 K(-101.6%) | -$12.67 M(+85.8%) |
| Mar 2024 | - | -$5.15 M(-17.5%) | -$6.82 M(-67.1%) |
| Dec 2023 | -$20.74 M(-72.0%) | -$6.24 M(+359.2%) | -$20.74 M(-43.1%) |
| Sept 2023 | - | -$1.36 M(-122.9%) | -$36.48 M(-25.0%) |
| June 2023 | - | $5.93 M(-131.1%) | -$48.62 M(-27.9%) |
| Mar 2023 | - | -$19.07 M(-13.2%) | -$67.42 M(-9.1%) |
| Dec 2022 | -$74.21 M(-1513.2%) | -$21.98 M(+63.0%) | -$74.21 M(+4.1%) |
| Sept 2022 | - | -$13.49 M(+4.8%) | -$71.29 M(+4.4%) |
| June 2022 | - | -$12.88 M(-50.2%) | -$68.27 M(>+9900.0%) |
| Mar 2022 | - | -$25.86 M(+35.6%) | -$584.00 K(-111.1%) |
| Dec 2021 | $5.25 M(-109.8%) | -$19.07 M(+82.1%) | $5.25 M(-36.3%) |
| Sept 2021 | - | -$10.47 M(-119.1%) | $8.24 M(-949.5%) |
| June 2021 | - | $54.81 M(-373.7%) | -$970.00 K(-98.6%) |
| Mar 2021 | - | -$20.03 M(+24.6%) | -$69.77 M(+30.5%) |
| Dec 2020 | -$53.45 M(+24.4%) | -$16.08 M(-18.3%) | -$53.45 M(+12.2%) |
| Sept 2020 | - | -$19.68 M(+40.6%) | -$47.63 M(+10.9%) |
| June 2020 | - | -$13.99 M(+278.2%) | -$42.95 M(-6.1%) |
| Mar 2020 | - | -$3.70 M(-63.9%) | -$45.72 M(+6.4%) |
| Dec 2019 | -$42.97 M(-28.3%) | -$10.26 M(-31.6%) | -$42.97 M(+103.3%) |
| Sept 2019 | - | -$14.99 M(-10.6%) | -$21.13 M(-19.9%) |
| June 2019 | - | -$16.77 M(+1672.3%) | -$26.38 M(-29.3%) |
| Mar 2019 | - | -$946.00 K(-108.2%) | -$37.29 M(-37.8%) |
| Dec 2018 | -$59.93 M(-22.9%) | $11.57 M(-157.2%) | -$59.93 M(-34.3%) |
| Sept 2018 | - | -$20.24 M(-26.9%) | -$91.28 M(+2.9%) |
| June 2018 | - | -$27.68 M(+17.3%) | -$88.70 M(+10.2%) |
| Mar 2018 | - | -$23.59 M(+19.3%) | -$80.51 M(+3.6%) |
| Dec 2017 | -$77.72 M(+1.3%) | -$19.77 M(+11.9%) | -$77.72 M(+10.4%) |
| Sept 2017 | - | -$17.67 M(-9.3%) | -$70.42 M(-6.8%) |
| June 2017 | - | -$19.48 M(-6.3%) | -$75.58 M(+1.1%) |
| Mar 2017 | - | -$20.80 M(+66.8%) | -$74.75 M(-2.5%) |
| Dec 2016 | -$76.69 M(+220.1%) | -$12.47 M(-45.4%) | -$76.69 M(-1.9%) |
| Sept 2016 | - | -$22.82 M(+22.3%) | -$78.15 M(+20.1%) |
| June 2016 | - | -$18.66 M(-17.9%) | -$65.09 M(+0.7%) |
| Mar 2016 | - | -$22.74 M(+63.2%) | -$64.66 M(+169.9%) |
| Dec 2015 | -$23.96 M(-65.9%) | -$13.93 M(+42.7%) | -$23.96 M(-5.0%) |
| Sept 2015 | - | -$9.76 M(-46.4%) | -$25.23 M(-25.4%) |
| June 2015 | - | -$18.22 M(-201.5%) | -$33.80 M(-5.1%) |
| Mar 2015 | - | $17.95 M(-218.1%) | -$35.60 M(-49.3%) |
| Dec 2014 | -$70.17 M(-19.6%) | -$15.20 M(-17.1%) | -$70.17 M(-5.2%) |
| Sept 2014 | - | -$18.34 M(-8.4%) | -$74.03 M(-3.3%) |
| June 2014 | - | -$20.02 M(+20.6%) | -$76.57 M(-2.0%) |
| Mar 2014 | - | -$16.61 M(-12.9%) | -$78.12 M(-10.5%) |
| Dec 2013 | -$87.30 M(-1.5%) | -$19.07 M(-8.6%) | -$87.30 M(-3.4%) |
| Sept 2013 | - | -$20.87 M(-3.2%) | -$90.40 M(+1.0%) |
| June 2013 | - | -$21.57 M(-16.4%) | -$89.54 M(+0.0%) |
| Mar 2013 | - | -$25.79 M(+16.3%) | -$89.53 M(+1.1%) |
| Dec 2012 | -$88.59 M | -$22.17 M(+10.8%) | -$88.59 M(+3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | -$20.01 M(-7.2%) | -$85.25 M(+8.5%) |
| June 2012 | - | -$21.56 M(-13.2%) | -$78.60 M(+4.9%) |
| Mar 2012 | - | -$24.85 M(+31.9%) | -$74.90 M(+4.5%) |
| Dec 2011 | -$71.68 M(-266.0%) | -$18.84 M(+41.1%) | -$71.68 M(+64.8%) |
| Sept 2011 | - | -$13.35 M(-25.2%) | -$43.50 M(-13.1%) |
| June 2011 | - | -$17.86 M(-17.4%) | -$50.05 M(-211.0%) |
| Mar 2011 | - | -$21.62 M(-331.5%) | $45.09 M(+4.4%) |
| Dec 2010 | $43.18 M(-142.0%) | $9.34 M(-146.9%) | $43.18 M(+310.4%) |
| Sept 2010 | - | -$19.91 M(-125.8%) | $10.52 M(+109.7%) |
| June 2010 | - | $77.28 M(-428.4%) | $5.02 M(-105.2%) |
| Mar 2010 | - | -$23.53 M(+0.9%) | -$97.38 M(-5.4%) |
| Dec 2009 | -$102.92 M(-2.9%) | -$23.32 M(-8.2%) | -$102.92 M(-4.2%) |
| Sept 2009 | - | -$25.41 M(+1.2%) | -$107.49 M(+0.3%) |
| June 2009 | - | -$25.12 M(-13.6%) | -$107.13 M(-0.5%) |
| Mar 2009 | - | -$29.07 M(+4.2%) | -$107.72 M(+1.6%) |
| Dec 2008 | -$106.03 M(+99.5%) | -$27.89 M(+11.3%) | -$106.03 M(+22.5%) |
| Sept 2008 | - | -$25.06 M(-2.5%) | -$86.58 M(+14.9%) |
| June 2008 | - | -$25.70 M(-6.1%) | -$75.32 M(+16.6%) |
| Mar 2008 | - | -$27.38 M(+224.2%) | -$64.63 M(+21.6%) |
| Dec 2007 | -$53.14 M(+44.6%) | -$8.44 M(-38.8%) | -$53.14 M(-4.8%) |
| Sept 2007 | - | -$13.80 M(-8.1%) | -$55.80 M(+11.0%) |
| June 2007 | - | -$15.01 M(-5.6%) | -$50.28 M(+19.3%) |
| Mar 2007 | - | -$15.89 M(+43.1%) | -$42.14 M(+14.7%) |
| Dec 2006 | -$36.75 M(-0.6%) | -$11.11 M(+34.2%) | -$36.75 M(+17.0%) |
| Sept 2006 | - | -$8.28 M(+20.5%) | -$31.40 M(-14.8%) |
| June 2006 | - | -$6.87 M(-34.6%) | -$36.87 M(-9.8%) |
| Mar 2006 | - | -$10.50 M(+82.4%) | -$40.89 M(+10.6%) |
| Dec 2005 | -$36.96 M(-6.9%) | -$5.76 M(-58.1%) | -$36.96 M(-0.6%) |
| Sept 2005 | - | -$13.75 M(+26.3%) | -$37.18 M(+4.9%) |
| June 2005 | - | -$10.89 M(+65.7%) | -$35.44 M(-0.5%) |
| Mar 2005 | - | -$6.57 M(+10.1%) | -$35.63 M(-10.2%) |
| Dec 2004 | -$39.70 M(+17.9%) | -$5.97 M(-50.3%) | -$39.70 M(-9.3%) |
| Sept 2004 | - | -$12.01 M(+8.5%) | -$43.78 M(+5.5%) |
| June 2004 | - | -$11.08 M(+4.1%) | -$41.49 M(+5.0%) |
| Mar 2004 | - | -$10.64 M(+5.8%) | -$39.50 M(+17.3%) |
| Dec 2003 | -$33.68 M(-6.9%) | -$10.05 M(+3.4%) | -$33.68 M(+5.4%) |
| Sept 2003 | - | -$9.72 M(+7.0%) | -$31.96 M(+3.5%) |
| June 2003 | - | -$9.09 M(+88.8%) | -$30.89 M(-10.0%) |
| Mar 2003 | - | -$4.82 M(-42.2%) | -$34.31 M(-5.1%) |
| Dec 2002 | -$36.16 M(+88.3%) | -$8.33 M(-3.7%) | -$36.16 M(+15.1%) |
| Sept 2002 | - | -$8.66 M(-30.8%) | -$31.41 M(+20.3%) |
| June 2002 | - | -$12.51 M(+87.6%) | -$26.12 M(+32.9%) |
| Mar 2002 | - | -$6.67 M(+86.1%) | -$19.65 M(+2.3%) |
| Dec 2001 | -$19.21 M(+26.3%) | -$3.58 M(+6.5%) | -$19.21 M(+22.9%) |
| Sept 2001 | - | -$3.36 M(-44.3%) | -$15.63 M(+27.4%) |
| June 2001 | - | -$6.04 M(-3.1%) | -$12.27 M(+96.9%) |
| Mar 2001 | - | -$6.23 M | -$6.23 M |
| Dec 2000 | -$15.21 M(+1.9%) | - | - |
| Dec 1999 | -$14.92 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual FCF year-on-year change?
- What is Rigel Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly FCF year-on-year change?
- What is Rigel Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM FCF year-on-year change?
What is Rigel Pharmaceuticals annual free cash flow?
The current annual FCF of RIGL is -$20.74 M
What is the all time high annual FCF for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual free cash flow is $43.18 M
What is Rigel Pharmaceuticals annual FCF year-on-year change?
Over the past year, RIGL annual free cash flow has changed by +$53.47 M (+72.05%)
What is Rigel Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of RIGL is $21.67 M
What is the all time high quarterly FCF for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly free cash flow is $77.28 M
What is Rigel Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, RIGL quarterly free cash flow has changed by +$23.03 M (+1694.48%)
What is Rigel Pharmaceuticals TTM free cash flow?
The current TTM FCF of RIGL is $10.36 M
What is the all time high TTM FCF for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM free cash flow is $45.09 M
What is Rigel Pharmaceuticals TTM FCF year-on-year change?
Over the past year, RIGL TTM free cash flow has changed by +$46.84 M (+128.39%)